Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅱ, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

NCT01935167 is registered in ClinicalTrials.gov with Dong Wha Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT01935167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01935167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅱ, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
Lead sponsor
Dong Wha Pharmaceutical Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
February 28, 2015
Enrollment
158 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy